6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 117-130

  Budihardjo, I Imawati ^a,c   Walker, Denise L ^a   Svingen, Phyllis A ^a   Buckwalter, Christopher A ^a   Desnoyers, Serge ^b,d   Eckdahl, Steven ^a   Shah, Girish M ^b   Poirier, Guy G ^b   Reid, Joel M ^a   Ames, Matthew M ^a   Kaufmann, Scott H ^a,e  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; 6 AMINONICOTINAMIDE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; DAUNORUBICIN; ETOPOSIDE; MELPHALAN;

APOPTOSIS; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CANCER CELL CULTURE; CELL STRAIN HL 60; CELL STRAIN K 562; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA ADDUCT; DNA DRUG COMPLEX; DRUG ACCUMULATION; DRUG METABOLISM; DRUG SENSITIZATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL;

6-AMINONICOTINAMIDE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DRUG SYNERGISM; HUMANS; NAD; POLY(ADP-RIBOSE) POLYMERASES; TUMOR CELLS, CULTURED;

EID: 0031882339     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Gately, D. P., and Howell, S. B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer, 67: 1171-1176, 1993.
2. Reed, E., and Kohn, K. W. Cisplatin and platinum analogs. In: B. A. Chabner and J. B. Collins (eds.), Cancer Chemotherapy: Principles and Practice, pp. 465-490. Philadelphia: J. B. Lippincott, 1990.
3. Sorenson, C. M., Barry, M. A., and Eastman, A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst., 82: 749-755, 1990.
4. Kaufmann, S. H. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
5. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
6. Perez, R. P., Hamilton, T. C., Ozols, R. F., and Young, R. C. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (Phila.), 71: 1571-1580, 1993.
7. Los, G., and Muggia, F. M. Platinum resistance. Experimental and clinical status. Hematol.-Oncol. Clin. N. Am., 8: 411-429, 1994.
8. O'Dwyer, P. J., Hamilton, T. C., Yao, K. S., Tew, K. D., and Ozols, R. F. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol.-Oncol. Clin. N. Am., 9: 383-396, 1995.
9. Larminat, F., and Bohr, V. A. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res., 22: 3005-3010, 1994.
10. O'Donovan, A., Davies, A. A., Moggs, J. G., West, S. C., and Wood, R. D. XPG endonuclease makes the 3′ incision in human DNA nucleotide excision repair. Nature (Lond.), 371: 432-435, 1994.
11. Vilpo, J. A., Vilpo, L. M., Szymkowski, D. E., O'Donovan, A., and Wood, R. D. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Mol. Cell. Biol., 15: 290-297, 1995.
12. Aebi, S., Kurdi-Haidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., Fishel, R., and Howell, S. B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 56: 3087-3090, 1996.
13. Drummond, J. T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and Adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem., 277: 19645-19648, 1996.
14. Perez, R. P., Hamilton, T. C., and Ozols, R. F. Resistance to alkylating agents and cisplatin. Insights from ovarian carcinoma model systems. Pharmacol. Ther., 48: 19-27, 1990.
15. Ding, R., Pommier, Y., Kang, V. H., and Smulson, M. Depletion of poly(ADP-ribose) polymerase by antisense RNA expression results in a delay in DNA strand break rejoining. J. Biol. Chem., 267: 12804-12812, 1992.
16. de Murcia, G., and Menissier de Murcia, J. Poly(ADP-ribose) polymerase. A molecular nick-sensor. Trends Biochem. Sci., 19: 172-176, 1994.
17. Ding, R., and Smulson, M. Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influences on genomic stability, chromatin organization, and carcinogen cytotoxicity. Cancer Res., 54: 4627-4634, 1994.
18. Stevnsner, T., Ding, R., Smulson, M., and Bohr, V. A. Inhibition of gene-specific repair of alkylation damage in cells depleted of poly(ADP-ribose) polymerase. Nucleic Acids Res., 22: 4620-4624, 1994.
19. Schreiber, V., Hunting, D., Trucco, C., Gowans, B., Grunwald, D., De Murcia, G., and De Murcia, J. M. A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. Proc. Natl. Acad. Sci. USA, 92: 4753-4757, 1995.
20. Le Cam, E., Fack, F., Menissier-de Murcia, J., Cognet, J. A., Barbin, A., Sarantoglou, V., Revet, B., Delain, E., and de Murcia, G. Conformational analysis of a 139 base-pair DNA fragment containing a single-stranded break and its interaction with human poly(ADP-ribose) polymerase. J. Mol. Biol., 235: 1062-1071, 1994.
21. Juarez-Salinas, H., Sims, J. L., and Jacobson, M. K. Poly(ADP-ribose) levels in carcinogen-treated cells. Nature (Lond.), 282: 740-741, 1979.
22. Alvarez-Gonzalez, R., and Jacobson, M. K. Characterization of polymers of adenoside diphosphate ribose generated in vitro and in vivo. Biochemistry, 26: 3218-3224, 1987.
23. Althaus, F. R., and Richter, C. ADP-ribosylation of proteins. Enzymology and biological significance. Mol. Biol. Biochem. Biophys., 37: 1-126, 1987.
24. Realini, C. A., and Althaus, F. R. Histone shuttling by poly(ADP-ribosylation). J. Biol. Chem., 267: 18858-18865, 1992.
25. + dependent repair of damaged DNA by human cell extracts. J. Biol. Chem., 268: 5480-5487, 1993.
26. Bürkle, A., Chen, G., Kupper, J. H., Grube, K., and Zeller, W. J. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis (Lond.), 14: 559-561, 1993.
27. Chen, G., and Zeller, W. J. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells. Anticancer Res., 14: 1462-1468, 1994.
28. Chen, G., and Zeller, W. J. Enhancement of cisplatin (CDDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. Cancer Chemother. Pharmacol., 26: 37-41, 1990.
29. Sims, J. L., Sikorski, G. W., Catino, D. M., Berger, S. J., and Berger, N. A. Poly(adenosinediphosphoribose) polymerase inhibitors stimulate unscheduled deoxyribonucleic acid synthesis in normal human lymphocytes. Biochemistry, 21: 1813-1821, 1982.
30. Stolfi, R. L., Colofiore, J. R., Nord, L. D., Koutcher, J. A., and Martin, D. S. Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Cancer Res., 52: 4074-4081, 1992.
31. Koutcher, J. A., Alfieri, A. A., Stolfi, R. L., Devitt, M. L., Colofiore, J. R., Nord, L. D., and Martin, D. S. Potentiation of a three drug chemotherapy regimen by radiation. Cancer Res., 53: 3518-3523, 1993.
32. Martin, D. S., Stolfi, R. L., Colofiore, J. R., Nord, L. D., and Sternberg, S. Biochemical modulation of tumor cell energy in vivo. II. A lower dose of Adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed. Cancer Invest., 12: 296-307, 1994.
33. Martin, D. S., Stolfi, R. L., Colofiore, J. R., and Nord, L. D. Marked enhancement in vivo of paclitaxel's (Taxol's) tumor-regressing activity by ATP-depleting modulation. Anticancer Drugs, 7: 655-659, 1996.
34. Herken, H., Lange, K., and Kolbe, H. Brain disorders induced by pharmacological blockade of the pentose phosphate pathway. Biochem. Biophys. Res. Commun., 36: 93-100, 1969.
35. 6-glial cells. Naunyn-Schmeideberg's Arch. Pharmacol., 294: 213-215, 1976.
36. Varnes, M. E. Inhibition of pentose cycle of A549 cells by 6-aminonicotinamide: consequences of aerobic and hypoxic radiation response and for radiosensitizer action. Natl. Cancer Inst. Monogr., 6: 199-203, 1988.
37. Hunting, D., Gowans, B., and Henderson, J. F. Effects of 6-aminonicotinamide on cell growth, poly(ADP-ribose) synthesis and nucleotide metabolism. Biochem. Pharmacol., 34: 3999-4003, 1985.
38. Berger, S. J., Manory, I., Sudar, D. C., Krothapalli, D., and Berger, N. A. Pyridine nucleotide analog interference with metabolic processes in mitogen-stimulated human T lymphocytes. Exp. Cell Res., 173: 379-387, 1987.
39. Berger, N. A., Berger, S. J., and Catino, D. M. Abnormal NAD+ levels in cells from patients with Fanconi's anaemia. Nature (Lond.), 299: 271-273, 1982.
40. Robins, H. I., Jonsson, G. G., Jackson, E. L., Schmitt, C. L., Cohen, J. D., and Jacobson, M. K. Effect of hyperthermia in vitro and in vivo on adenine and pyridine nucleotide pools in human peripheral lymphocytes. Cancer (Phila.), 67: 2096-2102, 1991.
41. Berger, N. A., Catino, D. M., and Vietti, T. J. Synergistic antileukemic effect of 6-aminonicotinamide and BCNU in L1210 cells in vitro and in vivo. Cancer Res., 42: 4382-4386, 1983.
42. 31P NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro. J. Biol. Chem., 271: 4113-4119, 1996.
43. Street, J. C., Alfieri, A. A., and Koutcher, J. A. Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Res., 57: 3956-3962, 1997.
44. Pike, B. L., and Robinson, W. A. Human bone marrow colony growth in agar-gel. J. Cell. Physiol., 76: 77-84, 1970.
45. McCloskey, D. E., Kaufmann, S. H., Prestigiacomo, L. J., and Davidson, N. E. Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells. Clin. Cancer Res., 2: 847-854, 1996.
46. Martins, L. M., Mesner, P. W., Kottke, T. J., Basi, G. S., Sinha, S., Tung, J. S., Svingen, P. A., Madden, B. J., Takahashi, A., McCormick, D. J., Earnshaw, W. C., and Kaufmann, S. H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood, 90: 4283-4296, 1997.
47. Johnson, S. W., Perez, R. P., Godwin, A. K., Yeung, A. T., Handel, L. M., Ozols, R. F., and Hamilton, T. C. Role of platinum-DNA adduct formation and removal of cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 47: 689-697, 1994.
48. Adjei, A. A., Budihardjo, I., Rowinsky, E. K., Kottke, T. J., Svingen, P. A., Buckwalter, C. A., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin. Cancer Res., 3: 761-770, 1997.
49. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
50. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. Specific proteolytic fragmentation of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
51. Eyer, P., and Podhradsky, D. Evaluation of the micromethod for determination of glutathione using enzymatic cycling and Ellman's reagent. Anal. Biochem., 153: 57-66, 1986.
52. Shah, G. M., Poirier, D., Duchaine, C., Brochu, G., Desnoyers, S. P., Lagueux, J., Verreault, A., Hoflack, J. C., Kirkland, J. B., and Poirier, G. G. Methods for biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo. Anal. Biochem., 227: 1-13, 1995.
53. Haid, E. D-Gluconate-6-phosphate. In: H. U. Bergmeyer (ed.), Methods of Enzymatic Analysis. Vol. II, pp. 1248-1251. New York: Academic Press, Inc., 1974.
54. Olsson, A., Olofsson, T., and Pero, R. W. Specific binding and uptake of extracellular nicotinamide in human leukemic K-562 cells. Biochem. Pharmacol., 45: 1191-1200, 1993.
55. Witholt, B. A bioautographic procedure for detecting TPN, DPN, NMN and NR. Methods Enzymol., 18: 813-816, 1971.
56. Anderson, B. M., and Anderson, C. D. Preparation and characterization of the NAD vinylogue, 3-pyridylacryloamide adenine dinucleotide. Anal. Biochem., 195: 57-62, 1991.
57. Evans, D. L., and Dive, C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res., 53: 2133-2139, 1993.
58. Lee, K. B., Parker, R. J., Bohr, V., Cornelison, T., and Reed, E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis (Lond.), 14: 2177-2180, 1993.
59. Masuda, H., Tanaka, T., Matsuda, H., and Kusaba, I. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res., 50: 1863-1866, 1990.
60. Kelland, L. R., Mistry, P., Abel, G., Freidlos, F., Loh, S. Y., Roberts, J. J., and Harrap, K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res., 52: 1710-1716, 1992.
61. Oldenburg, J., Begg, A. C., van Vugt, M. J. H., Ruevekamp, M., Schornagel, J. H., Pinedo, H. M., and Los, G. Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. Cancer Res., 54: 487-493, 1994.
62. Shah, G. M., Poirier, D., Desnoyers, S., Saint-Martin, S., Hoflack, J. C., Rong, P., ApSimon, M., Kirkland, J. B., and Poirier, G. G. Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress. Biochim. Biophys. Acta, 1312: 1-7, 1996.
63. Banasik, M., Komura, H., Shimoyama, M., and Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem., 267: 1569-1575, 1992.
64. Kaplan, N. O., Goldin, A., Humphreys, S. R., Ciotti, M. M., and Venditti, J. M. Significance of enzymatically catalyzed exchange reactions in chemotherapy. Science (Washington DC), 120: 437-440, 1954.
65. Carmona, A., and Freedland, R. A. Effect of 6-aminonicotinamide on pentose cycle activity in isolated hepatocytes. Int. J. Biochem., 22: 595-599, 1990.
66. Chatterjee, S., Cheng, M-F., Berger, R. B., Berger, S. J., and Berger, N. A. Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of GRP78 and subsequent development of resistance to etoposide. Cancer Res., 55: 868-883, 1995.
67. Buckwalter, C. A., Lin, A. H., Tanizawa, A., Pommier, Y. G., Cheng, Y-C., and Kaufmann, S. H. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res., 56: 1647-1681, 1996.
68. Byfield, J. E., and Calabro-Jones, P. M. Carrier-dependent and carrier-dependent transport of anti-cancer alkylating agents. Nature (Lond.), 294: 281-283, 1981.
69. Shionoya, S., Lu, Y., and Scanlon, K. J. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Res., 46: 3445-3448, 1986.
70. 14C utilization by the 755 tumor and host liver tissue. Cancer Res., 28: 1652-1654, 1968.
71. Colofiore, J. R., Stolfi, R. L., Nord, L. D., and Martin, D. S. Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression. Biochem. Pharmacol., 50: 1943-1948, 1995.
72. Martin, D. S., Stolfi, R. L., and Colofiore, J. R. Perspective. The chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest., 15: 372-381, 1997.
73. Mesner, P., Budihardjo, I., and Kaufmann, S. H. Chemotherapy-induced apoptosis. Adv. Pharmacol., 41: 461-499, 1997.
74. Reed, J. C. Bcl-2 family proteins: strategies for overcoming chemoresistance in cancer. Adv. Pharmacol., 41: 501-532, 1997.
75. 31P-magnetic resonance spectroscopic study. Biochem. Biophys. Res. Commun., 164: 947-953, 1989.
76. Belfi, C. A., Chatterjee, S., Gosky, D. M., Berger, S. J., and Berger, N. A. Colon cancer cells exhibit increased in vitro sensitivity to cross-linking alkylating agents after 6-aminonicotinamide treatment. Proc. Am. Assoc. Cancer Res., 37: 377, 1996.
77. Goldenberg, G. J., Lam, H. Y. P., and Begleiter, A. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem., 254: 1057-1064, 1979.
78. Tew, K. D., Colvin, M., and Chabner, B. A. Alkylating agents. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 297-332. Philadelphia: Lippincott-Raven Publishers, 1996.
79. Goldenberg, G. J., Vanstone, C. L., Israels, L. G., Ilse, D., and Bihler, I. Evidence for a transport carrier of nitrogen mustard in nitrogen mustard-sensitive and -resistant L5178Y lymphoblasts. Cancer Res., 30: 2285-2291, 1970.
80. Cheeseman, C. I. Molecular mechanisms involved in the regulation of amino acid transport. Prog. Biophys. Mol. Biol., 55: 71-84, 1991.
81. Saunders, P. O., Muhs, M. A., and Arimilli, S. Mechanisms of resistance to 6-aminonicotinamide. Anticancer Res., 16: 843-848, 1996.
82. Berger, N. A., Berger, S. J., and Hirschler, N. V. Pyridine nucleotide metabolism as a target for cancer chemotherapy, pp. 366-371. New York: Springer-Verlag, 1989.
83. Sternberg, S. S., and Philips, F. S. 6-Aminonicotinamide and acute degenerative changes in the central nervous system. Science (Washington DC), 127: 644-645, 1958.
84. Perlia, C. P., Kofman, S., Sky-Peck, H., and Taylor, S. I. Clinical use of 6-aminonicotinamide in patients with disseminated neoplastic disease. Cancer (Phila.), 14: 644-648, 1961.
85. Herter, F. P., Weissman, S. G., Thompson, H. G., Jr., Hyman, G., and Martin, D. S. Clinical experience with 6-aminonicotinamide. Cancer Res., 21: 31-37, 1961.